April 28, 2022 |
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
VBI Vaccines Announces Results of Annual General Meeting